Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02264613 · ClinicalTrials.gov registry record · Phase 1
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
A Phase 1 study, sponsored by Aileron Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 142
- Enrollment target
NCT02264613 is a Phase 1 study that has completed, run by Aileron Therapeutics. The registered enrollment target is 142 participants.
The verdict
NCT02264613, a Phase 1 study, has completed, sponsored by Aileron Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 142 participants
- Enrollment target
Study Summary
This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53.
Interventions
- DRUG ALRN-6924
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2014-10 |
| Est. Completion | 2020-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02264613
The ClinicalTrials.gov registry entry for NCT02264613 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aileron Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALRN-6924 is the first listed.
NCT02264613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02264613 about?
NCT02264613 is a clinical study titled "ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas". This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53.
What is the current status of trial NCT02264613?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 142 participants. The study started on 2014-10. Estimated completion is 2020-04.
What interventions are being tested in trial NCT02264613?
The interventions under investigation include: ALRN-6924 (DRUG).
Who is sponsoring clinical trial NCT02264613?
This trial is sponsored by Aileron Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.